• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    January 30, 2025 - FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

    1/30/25 5:46:14 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VRTX alert in real time by email
    For Immediate Release:
    January 30, 2025

    Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals reach the brain.  

    Journavx is the first drug to be approved in this new class of pain management medicines.

    Pain is a common medical problem and relief of pain is an important therapeutic goal. Acute pain is short-term pain that is typically in response to some form of tissue injury, such as trauma or surgery. Acute pain is often treated with analgesics that may or may not contain opioids.

    The FDA has long supported development of non-opioid pain treatment. As part of the FDA Overdose Prevention Framework, the agency has issued draft guidance aimed at encouraging development of non-opioid analgesics for acute pain and awarded cooperative grants to support the development and dissemination of clinical practice guidelines for the management of acute pain conditions.  

    “Today’s approval is an important public health milestone in acute pain management,” said Jacqueline Corrigan-Curay, J.D., M.D., acting director of the FDA's Center for Drug Evaluation and Research. “A new non-opioid analgesic therapeutic class for acute pain offers an opportunity to mitigate certain risks associated with using an opioid for pain and provides patients with another treatment option. This action and the agency’s designations to expedite the drug’s development and review underscore FDA’s commitment to approving safe and effective alternatives to opioids for pain management.”

    The efficacy of Journavx was evaluated in two randomized, double-blind, placebo- and active-controlled trials of acute surgical pain, one following abdominoplasty and the other following bunionectomy. In addition to receiving the randomized treatment, all participants in the trials with inadequate pain control were permitted to use ibuprofen as needed for “rescue” pain medication. Both trials demonstrated a statistically significant superior reduction in pain with Journavx compared to placebo.

    The safety profile of Journavx is primarily based on data from the pooled, double-blind, placebo- and active-controlled trials in 874 participants with moderate to severe acute pain following abdominoplasty and bunionectomy, with supportive safety data from one single-arm, open-label study in 256 participants with moderate to severe acute pain in a range of acute pain conditions.

    The most common adverse reactions in study participants who received Journavx were itching, muscle spasms, increased blood level of creatine phosphokinase, and rash. Journavx is contraindicated for concomitant use with strong CYP3A inhibitors. Additionally, patients should avoid food or drink containing grapefruit when taking Journavx.

    The application received Breakthrough Therapy, Fast Track and Priority Review designations by the FDA.  

    The FDA granted approval of Journavx to Vertex Pharmaceuticals Incorporated.

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.


    Inquiries

    Media:
    FDA Office of Media Affairs
    301-796-4540
    Consumer:
    888-INFO-FDA

    Get the next $VRTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VRTX

    DatePrice TargetRatingAnalyst
    5/7/2025Outperform → Peer Perform
    Wolfe Research
    5/6/2025$503.00Outperform → Market Perform
    Leerink Partners
    4/22/2025$535.00Overweight
    Cantor Fitzgerald
    2/12/2025$408.00 → $424.00Sell → Hold
    Canaccord Genuity
    2/11/2025Sell → Hold
    Canaccord Genuity
    1/30/2025$460.00Overweight → Equal Weight
    Wells Fargo
    12/20/2024$600.00 → $535.00Buy
    H.C. Wainwright
    12/19/2024Outperform → Perform
    Oppenheimer
    More analyst ratings

    $VRTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • January 30, 2025 - FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

      For Immediate Release: January 30, 2025 Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals reach the brain.  Journavx is the first dr

      1/30/25 5:46:14 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

      For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

      12/8/23 11:12:21 AM ET
      $BLUE
      $VRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • FDA Approval for TRIKAFTA (COPACKAGED) issued to VERTEX PHARMS INC

      Submission status for VERTEX PHARMS INC's drug TRIKAFTA (COPACKAGED) (SUPPL-11) with active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR has changed to 'Approval' on 08/03/2023. Application Category: NDA, Application Number: 212273, Application Classification: Labeling

      8/4/23 4:36:00 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Vertex Appoints Nancy Thornberry to its Board of Directors

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Nancy Thornberry has been appointed to its Board of Directors as an independent director. Ms. Thornberry has more than 35 years of experience in the pharmaceutical and biotech industries, spanning drug discovery, development and commercialization. She founded and served as Chief Executive Officer of Kallyope until 2021 and remains on its Board of Directors and is Chair of Research & Development. Prior to joining Kallyope, Ms. Thornberry spent more than 30 years at Merck & Co., Inc., most recently as Senior Vice President and Global Franchise Head, Diabetes and Endocrinology, with responsibility for discovery and clinical

      12/5/23 4:01:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Appoints Michel Lagarde to its Board of Directors

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Michel Lagarde has been appointed to its Board of Directors as an independent director. Mr. Lagarde is a senior health care and business leader with global expertise, currently serving as Chief Operating Officer and Executive Vice President of Thermo Fisher Scientific Inc. Prior to Thermo Fisher, Mr. Lagarde served as President and Chief Operating Officer of Patheon, a contract manufacturer to the biopharma industry, and as a Managing Director at JLL Partners, a private equity firm investing in health care services. "We are delighted to have Michel join the Vertex Board. His deep experience across numerous segments of

      10/5/23 8:00:00 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that E. Morrey Atkinson, Ph.D., has been appointed Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations, effective immediately. Dr. Atkinson has served as Senior Vice President of Global Commercial Manufacturing and Supply Chain since July 2020. This new role and function unifies responsibility for small molecule, cell and gene therapies across preclinical, clinical and commercial biopharmaceutical sciences, manufacturing operations and global supply chain. "Over the last three years, Morrey has played a vital role in building out our commercial manufa

      8/29/23 9:00:00 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Vertex Pharma downgraded by Wolfe Research

      Wolfe Research downgraded Vertex Pharma from Outperform to Peer Perform

      5/7/25 8:37:12 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Pharma downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Vertex Pharma from Outperform to Market Perform and set a new price target of $503.00

      5/6/25 8:04:29 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald resumed coverage on Vertex Pharma with a new price target

      Cantor Fitzgerald resumed coverage of Vertex Pharma with a rating of Overweight and set a new price target of $535.00

      4/22/25 7:35:34 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vertex Reports First Quarter 2025 Financial Results

      — Total revenue of $2.77 billion, a 3% increase compared to Q1 2024; raised the low end of total revenue guidance by $100 million to a new range of $11.85 to $12 billion — — Strong progress with CASGEVY®, ALYFTREK™ and JOURNAVX™ launches — — Povetacicept (pove) IgAN Phase 3 interim analysis (IA) cohort fully enrolled and zimislecel Phase 3 program to complete dosing this quarter, setting up potential filings in 2026; inaxaplin Phase 3 IA cohort on track to complete enrollment in the second half of 2025 — — Four programs already in pivotal development, with pivotal study of pove in primary membranous nephropathy (pMN) to start this year — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

      5/5/25 4:01:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner International Award "for pioneering research into the cellular and molecular mechanisms underlying the genetic disease cystic fibrosis, leading to the development of transformative drug therapies based on these mechanisms, thereby improving and saving countless lives." Negulescu shares the award with Michael J. Welsh, M.D., University of Iowa. "For more than 20 years, Paul and the team of dedicated Vertex researchers have focused on discovering and developing breakthrough therapies for people living with cystic fibrosis (CF). P

      4/11/25 5:30:00 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex to Announce First Quarter 2025 Financial Results on May 5th

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its first quarter 2025 financial results on Monday, May 5, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals First Quarter 2025 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast

      4/7/25 4:05:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRTX
    Financials

    Live finance-specific insights

    See more
    • Vertex Reports First Quarter 2025 Financial Results

      — Total revenue of $2.77 billion, a 3% increase compared to Q1 2024; raised the low end of total revenue guidance by $100 million to a new range of $11.85 to $12 billion — — Strong progress with CASGEVY®, ALYFTREK™ and JOURNAVX™ launches — — Povetacicept (pove) IgAN Phase 3 interim analysis (IA) cohort fully enrolled and zimislecel Phase 3 program to complete dosing this quarter, setting up potential filings in 2026; inaxaplin Phase 3 IA cohort on track to complete enrollment in the second half of 2025 — — Four programs already in pivotal development, with pivotal study of pove in primary membranous nephropathy (pMN) to start this year — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

      5/5/25 4:01:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex to Announce First Quarter 2025 Financial Results on May 5th

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its first quarter 2025 financial results on Monday, May 5, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals First Quarter 2025 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast

      4/7/25 4:05:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Reports Fourth Quarter and Full Year 2024 Financial Results

      — Full year product revenue of $11.02 billion, a 12% increase compared to full year 2023 — — Company provides full year 2025 total revenue guidance of $11.75 to $12.0 billion — — ALYFTREK™ approved in the U.S. for patients ages 6+ with cystic fibrosis; JOURNAVX™ approved in the U.S. for moderate-to-severe acute pain — — Diverse late-stage clinical pipeline accelerates with four programs in pivotal development — — Stuart Arbuckle, Chief Operating Officer, announces intent to retire July 1, 2025; as part of planned transition, Charlie Wagner, Chief Financial Officer, to assume additional role of Chief Operating Officer; Duncan McKechnie, SVP and current head of North America Commercia

      2/10/25 4:01:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Upadhyay Suketu returned 1,001 shares to the company and was granted 796 shares, decreasing direct ownership by 8% to 2,354 units (SEC Form 4)

      4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

      5/5/25 5:00:58 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Thornberry Nancy was granted 398 shares, increasing direct ownership by 24% to 2,035 units (SEC Form 4)

      4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

      5/5/25 4:59:17 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Schneider Jennifer was granted 796 shares, increasing direct ownership by 86% to 1,718 units (SEC Form 4)

      4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

      5/5/25 4:57:54 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRTX
    SEC Filings

    See more

    $VRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form 10-Q filed by Vertex Pharmaceuticals Incorporated

      10-Q - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)

      5/6/25 4:04:39 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Pharmaceuticals Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)

      5/5/25 4:10:03 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Vertex Pharmaceuticals Incorporated

      DEFA14A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)

      4/3/25 4:04:58 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

      SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

      4/10/24 12:14:10 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

      SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

      2/13/24 5:17:31 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

      SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

      2/9/24 6:19:03 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care